Evidence map›Paper›PMID 39416742›Full record

ArticleThe Malaysian journal of medical sciences : MJMS2024

Honeyomics and Industrialisation of Madu Kelulut as a Health Supplement: Are We Ready for Scale-Up?

Mohd Zulkifli Mustafa, Patricia Vit

Abstract readEditorial
In one paragraph

Article in The Malaysian journal of medical sciences : MJMS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Kelulut honey (Toxicology reports · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mohd Zulkifli MustafaDepartment of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
Patricia VitApitherapy and Bioactivity, Food Science Department, Faculty of Pharmacy and Bioanalysis, Universidad de Los Andes, Mérida, Venezuela.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ethnomedicinal uses of honey value its nutritional and medicinal properties to attain general health, diseases prevention or treatment for particular illness. Madu kelulut or stingless bee honey is produced by Meliponini species and the honey referred as superfood in Malaysia. The honey is a complete natural food product that provide safe source of energy via low GI trehalulose sugar, nourished with nutrients, vitamins, amino acids and good bacteria that is formed via unique natural pot-bioreactor processing. The honey is gaining attention for its high antioxidant levels, antimicrobial properties, anti-inflammatory, unique composition and taste. Studies revealed multiple foundations and evidence-based that the madu kelulut is highly beneficial for human possessing a promising niche in the health supplement industry with economic importance projected up to USD700 million in local markets. Honeyomics of madu kelulut aims at understanding the economic importance factors that contribute to the entire mark-up of madu kelulut as general guides for standards and the functional properties of madu kelulut. Several milestones (2005-2023) have been achieved which acknowledge the strategic development and ecosystem for the madu kelulut industry in Malaysia. Further efforts to safeguards the quality and authenticity of stingless bee honey via modernisation, capacity building and market expansion could encourage for scale-up and solidifying Malaysia's position as a key player in the global stingless bee honey industry, providing economic benefits while preserving natural resources for future generations.

Indexed as

commercialisationhealth supplementhoneyomicsmadu kelulutsuperfood

Identifiers

PMID39416742
PMCPMC11477472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.